Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer
Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer
复制标题
DOI：
10.1007/s10549-007-9645-1
复制
发表时间：
2008-05-01
影响因子：
3.8
通讯作者：
Ferno, Marten
中科院分区：
文献类型：
--
作者：
Dihge, Looket;Bendahl, Par-Ola;Ferno, Marten
据报道，表皮生长因子受体（EGFR）和雌激素受体（ER）调节剂乳腺癌扩增- 1 （AIB1）对乳腺癌患者的预后有重要影响。我们通过组织微阵列分析了297例原发性乳腺癌患者的AIB1和EGFR，以预测他莫昔芬辅助内分泌治疗两年后的预后。AIB1的高表达与DNA-非二倍体、高S期分数、HER2扩增和短期(
The epidermal growth factor receptor (EGFR) and the estrogen receptor (ER) modulator Amplified In Breast cancer- 1 (AIB1) have been reported to be of importance for the prognosis of breast cancer patients. We have analyzed AIB1 and EGFR by immunohistochemistry in primary breast cancers (n = 297) arranged in a tissue microarray in order to predict outcome after adjuvant endocrine therapy with tamoxifen for two years. High expression of AIB1 was associated with DNA- nondiploidy, high S- phase fraction, HER2 amplification, and short term (